A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer (NCT01120561)
This is a multicenter, open-label, single-arm, expanded access study designed to provide ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and efficacy of T-DM1 administered by intravenous (IV) infusion.
This trial is sponsored by Genentech, Inc. 
- Condition: Metastatic Breast Cancer
- Phase: II
- Estimated Enrollment:
- Last verified: May 2013
Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.